The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > November 21, 2025
Daily News
November 21, 2025
- Patient Groups Push Back against Delisting OTC-Like Drugs; Panel Leans Toward Higher Copays
November 21, 2025
- Japan Approves Label Expansions for Braftovi, Augtyro, Uplizna, and More
November 21, 2025
- Japan Panel OKs NIP Use of Maternal RSV Vaccine from FY2026
November 21, 2025
- Japan to Add High-Dose Flu Vaccine to NIP for Adults Aged 75 and Over
November 21, 2025
- Towa, Sawai Log H1 Sales Gains, but Overseas Woes and Litigation Drag on Profit
November 21, 2025
- 60% of Japan Drug Makers See Lower Operating Profit in H1 FY2025, R&D Costs Weigh on Mid-Sized Firms
November 21, 2025
- ViiV Japan Pushing Digital Tools to Support Patient-Doctor Communication
November 21, 2025
- Industry Groups Call for More Efficient Clinical Trials in Japan: Joint Statement
November 21, 2025
- MHLW Panel to Review Kissei’s Uterine Fibroid Drug, 3 More NMEs on December 3
November 21, 2025
- Japan OKs FoundationOne CDx for Augtyro’s NTRK Fusion Indication
November 21, 2025
- Ueno Signals Openness to Multiple Approaches on OTC-Like Drug Copays
November 21, 2025
- LDP Outlines Key Issues for FY2026 Budget, Copay Review for OTC-Like Drugs Included
November 21, 2025
- Japan to Tap National Anti-Flu Drug Stockpile during Severe Shortages: MHLW
November 21, 2025
- Ensure Sustainable Drug Pricing for National Security: LDP Health Division Chief
November 21, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…